Price T Rowe Associates Inc Blueprint Medicines Corp Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,415,837 shares of BPMC stock, worth $701 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
5,415,837
Previous 5,679,089
4.64%
Holding current value
$701 Million
Previous $495 Million
3.23%
% of portfolio
0.06%
Previous 0.06%
Shares
18 transactions
Others Institutions Holding BPMC
# of Institutions
385Shares Held
69.2MCall Options Held
1.54MPut Options Held
1.08M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$860 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$498 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$398 Million0.05% of portfolio
-
State Street Corp Boston, MA2.68MShares$347 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...